The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers

Karoly Szepeshazi, Norman L Block, Andrew V Schally

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Peptide hormones can influence the development and growth of many cancers which are not considered classical hormonedependent tumors. Analogs of somatostatin, bombesin/gastrin-releasing peptide (GRP), luteinizing hormone-releasing hormone (LH-RH) and growth hormone-releasing hormone (GH-RH) can interfere with receptors on tumor cells or intracellular pathways that are important in cell proliferation and in this way inhibit tumor growth. The first part of this review explains how these peptide hormones and their analogs affect tumors. The second part of this review describes how various hormone analogs can be used for the treatment of gastric, colorectal, pancreatic, liver and urinary bladder cancers. These tumors are major health problems worldwide and their treatment remains a great challenge. Receptors for somatostatin, bombesin/GRP, LH-RH and GH-RH are present in a large percentage of these cancers. We have developed a series of cytotoxic peptides based on doxorubicin or its derivative 2-pyrrolino-doxorubicin coupled to an analog of LH-RH, somatostatin or bombesin. This new class of targeted analogs might provide a more effective therapy for various cancers that express receptors for these carrier peptides, while producing significantly reduced peripheral toxicity. Under experimental conditions, these peptide hormone analogs strongly inhibited the growth of these tumors. Cytotoxic analogs were particularly effective on tumors that express the specific peptide receptors and acted more powerfully than the carrier peptide or the cytotoxic compound alone. Clinical trials on these peptide analogs are in progress.

Original languageEnglish (US)
Pages (from-to)103-110
Number of pages8
JournalHormone Molecular Biology and Clinical Investigation
Volume1
Issue number3
DOIs
StatePublished - Jan 1 2010

Fingerprint

Urinary Bladder Neoplasms
Peptides
Peptide Hormones
Liver
Neoplasms
Gonadotropin-Releasing Hormone
Gastrin-Releasing Peptide
Bombesin
Growth Hormone-Releasing Hormone
Peptide Receptors
Somatostatin
Doxorubicin
Bombesin Receptors
Somatostatin Receptors
Growth
Growth and Development
Stomach
Cell Proliferation
Clinical Trials
Hormones

Keywords

  • Gastrointestinal cancer
  • Liver cancer
  • Pancreatic cancer
  • Peptide hormones
  • Urinary bladder cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)
  • Molecular Biology
  • Endocrinology

Cite this

The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers. / Szepeshazi, Karoly; Block, Norman L; Schally, Andrew V.

In: Hormone Molecular Biology and Clinical Investigation, Vol. 1, No. 3, 01.01.2010, p. 103-110.

Research output: Contribution to journalReview article

@article{e125260450774fe79233d8e9789a9616,
title = "The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers",
abstract = "Peptide hormones can influence the development and growth of many cancers which are not considered classical hormonedependent tumors. Analogs of somatostatin, bombesin/gastrin-releasing peptide (GRP), luteinizing hormone-releasing hormone (LH-RH) and growth hormone-releasing hormone (GH-RH) can interfere with receptors on tumor cells or intracellular pathways that are important in cell proliferation and in this way inhibit tumor growth. The first part of this review explains how these peptide hormones and their analogs affect tumors. The second part of this review describes how various hormone analogs can be used for the treatment of gastric, colorectal, pancreatic, liver and urinary bladder cancers. These tumors are major health problems worldwide and their treatment remains a great challenge. Receptors for somatostatin, bombesin/GRP, LH-RH and GH-RH are present in a large percentage of these cancers. We have developed a series of cytotoxic peptides based on doxorubicin or its derivative 2-pyrrolino-doxorubicin coupled to an analog of LH-RH, somatostatin or bombesin. This new class of targeted analogs might provide a more effective therapy for various cancers that express receptors for these carrier peptides, while producing significantly reduced peripheral toxicity. Under experimental conditions, these peptide hormone analogs strongly inhibited the growth of these tumors. Cytotoxic analogs were particularly effective on tumors that express the specific peptide receptors and acted more powerfully than the carrier peptide or the cytotoxic compound alone. Clinical trials on these peptide analogs are in progress.",
keywords = "Gastrointestinal cancer, Liver cancer, Pancreatic cancer, Peptide hormones, Urinary bladder cancer",
author = "Karoly Szepeshazi and Block, {Norman L} and Schally, {Andrew V}",
year = "2010",
month = "1",
day = "1",
doi = "10.1515/HMBCI.2010.018",
language = "English (US)",
volume = "1",
pages = "103--110",
journal = "Hormone Molecular Biology and Clinical Investigation",
issn = "1868-1883",
publisher = "Walter de Gruyter GmbH",
number = "3",

}

TY - JOUR

T1 - The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers

AU - Szepeshazi, Karoly

AU - Block, Norman L

AU - Schally, Andrew V

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Peptide hormones can influence the development and growth of many cancers which are not considered classical hormonedependent tumors. Analogs of somatostatin, bombesin/gastrin-releasing peptide (GRP), luteinizing hormone-releasing hormone (LH-RH) and growth hormone-releasing hormone (GH-RH) can interfere with receptors on tumor cells or intracellular pathways that are important in cell proliferation and in this way inhibit tumor growth. The first part of this review explains how these peptide hormones and their analogs affect tumors. The second part of this review describes how various hormone analogs can be used for the treatment of gastric, colorectal, pancreatic, liver and urinary bladder cancers. These tumors are major health problems worldwide and their treatment remains a great challenge. Receptors for somatostatin, bombesin/GRP, LH-RH and GH-RH are present in a large percentage of these cancers. We have developed a series of cytotoxic peptides based on doxorubicin or its derivative 2-pyrrolino-doxorubicin coupled to an analog of LH-RH, somatostatin or bombesin. This new class of targeted analogs might provide a more effective therapy for various cancers that express receptors for these carrier peptides, while producing significantly reduced peripheral toxicity. Under experimental conditions, these peptide hormone analogs strongly inhibited the growth of these tumors. Cytotoxic analogs were particularly effective on tumors that express the specific peptide receptors and acted more powerfully than the carrier peptide or the cytotoxic compound alone. Clinical trials on these peptide analogs are in progress.

AB - Peptide hormones can influence the development and growth of many cancers which are not considered classical hormonedependent tumors. Analogs of somatostatin, bombesin/gastrin-releasing peptide (GRP), luteinizing hormone-releasing hormone (LH-RH) and growth hormone-releasing hormone (GH-RH) can interfere with receptors on tumor cells or intracellular pathways that are important in cell proliferation and in this way inhibit tumor growth. The first part of this review explains how these peptide hormones and their analogs affect tumors. The second part of this review describes how various hormone analogs can be used for the treatment of gastric, colorectal, pancreatic, liver and urinary bladder cancers. These tumors are major health problems worldwide and their treatment remains a great challenge. Receptors for somatostatin, bombesin/GRP, LH-RH and GH-RH are present in a large percentage of these cancers. We have developed a series of cytotoxic peptides based on doxorubicin or its derivative 2-pyrrolino-doxorubicin coupled to an analog of LH-RH, somatostatin or bombesin. This new class of targeted analogs might provide a more effective therapy for various cancers that express receptors for these carrier peptides, while producing significantly reduced peripheral toxicity. Under experimental conditions, these peptide hormone analogs strongly inhibited the growth of these tumors. Cytotoxic analogs were particularly effective on tumors that express the specific peptide receptors and acted more powerfully than the carrier peptide or the cytotoxic compound alone. Clinical trials on these peptide analogs are in progress.

KW - Gastrointestinal cancer

KW - Liver cancer

KW - Pancreatic cancer

KW - Peptide hormones

KW - Urinary bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=84865983293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865983293&partnerID=8YFLogxK

U2 - 10.1515/HMBCI.2010.018

DO - 10.1515/HMBCI.2010.018

M3 - Review article

AN - SCOPUS:84865983293

VL - 1

SP - 103

EP - 110

JO - Hormone Molecular Biology and Clinical Investigation

JF - Hormone Molecular Biology and Clinical Investigation

SN - 1868-1883

IS - 3

ER -